Kennedy: FDA Reviews Mifepristone Safety – Abortion Pill Concerns
- The Food and Drug Administration (FDA) is reviewing the safety of the abortion pill mifepristone, Health and Human Services Secretary Robert F.Kennedy Jr.
- Conservatives and anti-abortion groups have criticized the drug, notably after the Biden administration in 2023 made it possible for women to receive mifepristone via telehealth and by mail.
- The concerns raised center around potential dangers associated with offering mifepristone without sufficient medical support or supervision.
“`html
FDA Review of Mifepristone: Safety Concerns and Access Changes
Table of Contents
What is Mifepristone and Why is it Under Review?
The Food and Drug Administration (FDA) is reviewing the safety of the abortion pill mifepristone, Health and Human Services Secretary Robert F.Kennedy Jr. said in a recent letter to Republican state attorneys general. this review comes after years of increasing access to the drug and growing criticism from conservative and anti-abortion groups.
Conservatives and anti-abortion groups have criticized the drug, notably after the Biden administration in 2023 made it possible for women to receive mifepristone via telehealth and by mail. The majority of women who terminate pregnancies do so through medication abortions.
timeline of Events
- July 2023: Republican attorneys general wrote to Secretary Kennedy requesting a review of mifepristone’s safety.
- June 2023: Secretary Kennedy asked FDA Commissioner Martin Makary to “review the latest data” on the drug.
- September 19, 2023: Kennedy and Makary informed state attorneys general that HHS – through the FDA – is conducting its own review of the evidence relating to the safety and efficacy of mifepristone.
- 2023 (Ongoing): FDA review is underway, focusing on real-world outcomes and evidence.
What are the Specific Concerns?
The concerns raised center around potential dangers associated with offering mifepristone without sufficient medical support or supervision. The letter from Kennedy and Makary specifically referenced a study by the Ethics and Public Policy Center (EPPC).
According to EPPC, its study found nearly 11% of women “experience a serious adverse event” following a medication abortion. The letter also points to FDA data from 2000 to 2012, wich indicated 2,740 adverse events, including 416 events involving blood loss requiring transfusions. Critics argue that safeguards for women regarding the administration of mifepristone have been significantly reduced sence then.
Understanding Mifepristone and Medication Abortion
Mifepristone is a medication used in combination with misoprostol to terminate a pregnancy. It works by blocking the hormone progesterone,which is essential for maintaining a pregnancy. Medication abortion is a safe and effective method of terminating a pregnancy, but like all medical procedures, it carries some risks.